Who are Brivaracetam (ucb 34714)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Keppra, Standard dose topiramate, Topiramate-Implant, LEV, Topiramate Standard, Oral levetiracetam.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brivaracetam-ucb-34714.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Brivaracetam (ucb 34714) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brivaracetam (ucb 34714) (Brivaracetam (ucb 34714)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiepileptic agent; SV2A ligand. Area: Neurology.

phase 3 Antiepileptic agent; SV2A ligand SV2A (synaptic vesicle protein 2A) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Brivaracetam (ucb 34714) (Brivaracetam (ucb 34714)) — UCB Pharma. Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brivaracetam (ucb 34714) TARGET	Brivaracetam (ucb 34714)	UCB Pharma	phase 3	Antiepileptic agent; SV2A ligand	SV2A (synaptic vesicle protein 2A)
Keppra	levetiracetam	Generic (originally UCB Pharma)	marketed	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Topiramate-Implant	Topiramate-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor, sodium channels, glutamate receptors
LEV	LEV	GlaxoSmithKline	marketed	Antiepileptic agent	SV2A (synaptic vesicle glycoprotein 2A)
Topiramate Standard	Topiramate Standard	Janssen Korea, Ltd., Korea	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Oral levetiracetam	Oral levetiracetam	Children's Hospital of Fudan University	marketed	Antiepileptic agent	SV2A (synaptic vesicle protein 2A)

Recent regulatory actions (last 90 days)

2026-04-08 — Keppra · FDA · approved · US · Generic (originally UCB Pharma)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-03 — Keppra · 8163306 · Formulation · US
2027-10-31 — Keppra · 8431156 · Formulation · US
2027-10-31 — Keppra · 8470367 · Formulation · US
2028-09-17 — Keppra · 7858122 · Formulation · US
2031-06-07 — Keppra · 8802142 · Formulation · US
2031-12-07 — Keppra · 8802142*PED · Compound · US
2034-03-14 — Keppra · 11160786 · Formulation · US
2034-03-14 — Keppra · 9669009 · Method of Use · US
2034-03-14 — Keppra · 9339489 · Formulation · US

Sponsor landscape (Antiepileptic agent; SV2A ligand class)

UCB Pharma · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brivaracetam (ucb 34714) — Competitive Intelligence Brief. https://druglandscape.com/ci/brivaracetam-ucb-34714. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab